Fig 1.
Article identification and selection: Preferred reporting items for systematic reviews and meta-analyses from the systematic literature review of clinical trials in newly diagnosed multiple myeloma.
Table 1.
Characteristics and endpoint availability in identified studies.
Fig 2.
Scatterplots of CR and ORR on median PFS months.
Scatterplots depict the unadjusted linear model overlayed on the raw data, with point size indicating the relative sample size of each study arm for A) PFS vs ORR and B) PFS vs CR. Dashed lines demonstrate the interpretation of the unadjusted model coefficients. CI, confidence interval; CR, complete response; BOR, bortezomib; LEN, lenalidomide; ORR, overall response rate; PFS, progression-free survival.
Table 2.
Modeling results for ORR and CR as predictors of median PFS.
Fig 3.
Scatterplots of sCR and MRD on median PFS months.
Scatterplots depict the unadjusted linear model overlayed on the raw data, with point size indicating the relative sample size of each study arm for A) PFS vs sCR (%) and B) PFS vs MRD (%). Dashed lines demonstrate the interpretation of the unadjusted model coefficients. CI, confidence interval; BOR, bortezomib; LEN, lenalidomide; MRD, minimal residual disease; ORR, overall response rate; PFS, progression-free survival; sCR, stringent complete response.
Table 3.
Modeling results for sCR and MRD as predictors of median PFS.